Parkinson's disease: progression and mortality in the L-DOPA era.
Di Rocco
A
A
Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029, USA.
Molinari
S P
SP
Kollmeier
B
B
Yahr
M D
MD
D000328:Adult; D017668:Age of Onset; D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002423:Cause of Death; D003704:Dementia / Q000150:complications; D018450:Disease Progression; D004409:Dyskinesia, Drug-Induced / Q000150:complications / Q000453:epidemiology / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007024:Hypotension, Orthostatic / Q000150:complications / Q000503:physiopathology; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use*; D008017:Life Expectancy; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000401:mortality* / Q000503:physiopathology; D016019:Survival Analysis
D000978:Antiparkinson Agents; D007980:Levodopa